Physician profile
Nehal Singh
NPI 1750497293
$20,166.04
in general payments reported to CMS, 2019-2025
50 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,329 · 2020: $2,598 · 2021: $3,827 · 2022: $3,202 · 2023: $2,642 · 2024: $2,999 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,150 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,150.47 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,507.47 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $2,161.72 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,836.51 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,517.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,268.26 | 2019-2025 | |
| Amgen INC. | $1,209.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $991.73 | 2020-2025 | Penmenvy, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $847.66 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $838.11 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $792.84 | 2023-2025 | Auvelity, Symbravo |
| Novo Nordisk INC | $724.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $604.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $488.93 | 2020-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $478.50 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Biohaven Pharmaceutical Holding Company LTD. | $433.57 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.